Epizyme (EPZM) Upgraded by BidaskClub to “Hold”
Epizyme (NASDAQ:EPZM) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday.
EPZM has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Epizyme in a research note on Wednesday, June 27th. Zacks Investment Research cut Epizyme from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Leerink Swann cut Epizyme from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a research note on Tuesday, July 3rd. Morgan Stanley set a $12.00 target price on Epizyme and gave the company a “hold” rating in a research note on Friday, September 7th. Finally, ValuEngine cut Epizyme from a “hold” rating to a “sell” rating in a research note on Thursday, June 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $21.00.
Epizyme stock opened at $10.15 on Thursday. The company has a market cap of $712.41 million, a PE ratio of -4.66 and a beta of 1.81. Epizyme has a 52 week low of $8.61 and a 52 week high of $21.40.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Spark Investment Management LLC bought a new position in Epizyme during the second quarter worth $597,000. Trexquant Investment LP bought a new position in Epizyme during the second quarter worth $328,000. UBS Group AG lifted its stake in Epizyme by 846.7% during the first quarter. UBS Group AG now owns 114,740 shares of the biopharmaceutical company’s stock worth $2,037,000 after purchasing an additional 102,620 shares during the last quarter. Alps Advisors Inc. lifted its stake in Epizyme by 8.5% during the second quarter. Alps Advisors Inc. now owns 100,842 shares of the biopharmaceutical company’s stock worth $1,366,000 after purchasing an additional 7,918 shares during the last quarter. Finally, Citadel Advisors LLC increased its position in Epizyme by 39.3% in the second quarter. Citadel Advisors LLC now owns 810,119 shares of the biopharmaceutical company’s stock worth $10,977,000 after buying an additional 228,405 shares during the period. Hedge funds and other institutional investors own 85.06% of the company’s stock.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Recommended Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.